Compare Lowe`s Companies Inc (LOW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Sana Biotechnology Inc — how do they compare? Lowe`s Companies Inc trades at $216.7 (market cap $124.06B), while Sana Biotechnology Inc trades at $3.83 (market cap $1.13B). The key difference: Lowe`s Companies Inc is far larger — about 109.8× Sana Biotechnology Inc's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| LOW | SANA | |
|---|---|---|
Market Cap | $124.06B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $5.92 |
52-Week Low | $201.92 | $2.68 |
Enterprise Value | $165.81B | $1.05B |
Dividend Yield | 2.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $216.14, down 1.23% with a bullish technical outlook supported by moving averages. The company maintains solid fundamentals with consistent earnings beats and a 7.51% net margin, though revenue declined to $83.67B in 2025. Analyst consensus remains strongly positive with a $257.06 price target and 61% buy ratings. Recent news highlights upcoming Q2 2026 earnings and community investments.
LOW presents a compelling investment case with strong analyst support and stable cash flows, but faces risks from competitive pressures and declining revenue trends. The stock's current valuation at 18.7x P/E appears reasonable given earnings consistency, though investors should monitor same-store sales performance in the upcoming earnings report.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
